Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) receives new coverage from StockNews.com analysts

0

Equity researchers at StockNews.com began to cover the shares of Fresenius Medical Care AG & Co. KGaA (NYSE: FMS – Get a rating) in a research note published Wednesday. The company has attached a “buy” rating to the stock.

FMS has been the subject of a number of other reports. DZ Bank reduced shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “hold” rating in a Friday, July 29 research note. UBS Group downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a Friday, July 29 research note. Berenberg Bank cut its price target on shares of Fresenius Medical Care AG & Co. KGaA from €76.70 ($78.27) to €57.95 ($59.13) in a Wednesday 10 research note august. JPMorgan Chase & Co. cut its price target on shares of Fresenius Medical Care AG & Co. KGaA from €51.00 ($52.04) to €23.00 ($23.47) in a research note Monday, August 1. Finally, Truist Financial cut its price target on shares of Fresenius Medical Care AG & Co. KGaA from $34.00 to $27.00 and set a “hold” rating for the company in a research note from the Wednesday, June 22. One financial analyst has assigned the stock a sell rating, eight have issued a hold rating and three have assigned the stock a buy rating. According to MarketBeat, Fresenius Medical Care AG & Co. KGaA currently has a consensus rating of “Hold” and an average target price of $45.83.

Pricing performance of Fresenius Medical Care AG & Co. KGaA

NYSE FMS opened at $13.13 on Wednesday. The company has a quick ratio of 0.85, a current ratio of 1.18 and a debt ratio of 0.47. The stock has a market capitalization of $7.69 billion, a PE ratio of 8.36, a price-to-growth earnings ratio of 0.67 and a beta of 1.06. The company has a 50-day moving average price of $16.54 and a two-hundred-day moving average price of $24.12. Fresenius Medical Care AG & Co. KGaA has a 12-month low of $12.78 and a 12-month high of $36.08.

Fresenius Medical Care AG & Co. KGaA (NYSE: FMS – Get a rating) last released its results on Thursday, July 28. The company reported earnings per share (EPS) of $0.41 for the quarter, missing analyst consensus estimates of $0.45 per ($0.04). The company posted revenue of $5.07 billion in the quarter, versus analyst estimates of $4.80 billion. Fresenius Medical Care AG & Co. KGaA achieved a net margin of 4.42% and a return on equity of 6.70%. As a group, stock analysts predict that Fresenius Medical Care AG & Co. KGaA will post earnings per share of 1.64 for the current fiscal year.

Institutional investors weigh in on Fresenius Medical Care AG & Co. KGaA

Several institutional investors and hedge funds have recently bought and sold shares of FMS. Wulff Hansen & CO. acquired a new stake in Fresenius Medical Care AG & Co. KGaA in Q4, valued at $351,000. Cacti Asset Management LLC increased its stake in Fresenius Medical Care AG & Co. KGaA by 35.8% in the 1st quarter. Cacti Asset Management LLC now owns 36,000 shares of the company valued at $1,212,000 after purchasing an additional 9,500 shares during the period. Cascade Investment Advisors Inc. increased its equity stake in Fresenius Medical Care AG & Co. KGaA by 2.3% in Q1. Cascade Investment Advisors Inc. now owns 32,260 shares of the company worth $1,087,000 after purchasing an additional 725 shares in the last quarter. Creative Financial Designs Inc. ADV purchased a new stake in shares of Fresenius Medical Care AG & Co. KGaA in Q1 for a value of approximately $67,000. Finally, Capital Insight Partners LLC increased its stake in Fresenius Medical Care AG & Co. KGaA shares by 15.8% in the 1st quarter. Capital Insight Partners LLC now owns 70,740 shares of the company worth $2,383,000 after purchasing an additional 9,648 shares in the last quarter. Institutional investors hold 5.59% of the company’s shares.

About Fresenius Medical Care AG & Co. KGaA

(Get a rating)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America and abroad. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; equipment, training and patient support services including clinical monitoring, assisting with follow-up and arranging delivery of supplies to the patient’s home; and contracted dialysis services with hospitals in the United States for hospitalized patients with end-stage renal disease (ESRD) and for patients with acute renal failure.

Featured Articles

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (NYSE: FMS)

This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Before you consider Fresenius Medical Care AG & Co. KGaA, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes a turn… and Fresenius Medical Care AG & Co. KGaA was not on the list.

While Fresenius Medical Care AG & Co. KGaA currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here

Share.

Comments are closed.